Voytek Bereza, MPharm, IP

Prescribing Pharmacist
Sydney NSW
As part of a comprehensive, client-centered approach, I begin each therapeutic relationship by taking a thorough and detailed medical and psychosocial history. This includes reviewing current and past physical and mental health conditions, medication use, substance use history, trauma background, and personal or family history of psychiatric conditions. This careful assessment is essential to ensuring that any potential engagement with psychedelic therapy—whether legally sanctioned, personal, or hypothetical—is approached with informed caution, in alignment with current clinical guidelines. Once we’ve established a potential direction for therapy, we will collaboratively explore intentions, goals, and concerns around psychedelic use. This may include therapeutic, spiritual, or introspective motivations. At this stage, I introduce relevant, up-to-date research from the field of psychedelic science—covering topics such as neurobiology, therapeutic outcomes, integration processes, and potential risks. I find sharing research helps to demystify the experience, clarify realistic expectations, and empower clients with evidence-based information. I often find that discussing specific aspects of psychedelic experiences—such as ego dissolution, emotional catharsis, or altered states of consciousness—not only helps clients feel better prepared but also reduces any anticipatory anxiety around therapy. By approaching these conversations with curiosity, compassion, and non-judgment, clients are better able to express fears or misconceptions that might otherwise remain unspoken. Throughout the process, I emphasize harm reduction strategies such as set and setting, intention setting, dosage considerations, and the importance of support before, during, and after any psychedelic experience. I do not encourage or facilitate illegal activity; rather, I provide a safe, confidential space to support individuals wherever they are on their journey—whether they’re contemplating psychedelic use, have had challenging experiences in the past, or are seeking integration after a profound session. Ultimately, my role is to serve as an informed and compassionate guide, helping clients navigate their experiences with greater safety, insight, and emotional support.
I am a 40-year-old, GPhC licensed prescribing pharmacist from London, UK. I graduated from UCL in 2008 and went on to complete my UK-based independent prescriber course at King's College in 2014. After a decade of working in a community setting working with a wide range of patients with addiction and mental health issues, I started Voyager Medical. At the company, I worked to develop medical governance systems and clinical protocols to ensure medicine administration including psychedelics such as esketamine (Spravato) were administered to Best Practice.